Navigation Links
QRxPharma to Sponsor Symposium at 13th World Congress on Pain Meeting
Date:8/31/2010

r they are frequently of shorter duration among MoxDuo IR subjects than the controls.

According to a report published in 2006 in The British Journal of Pharmacology(1), the search for an analgesic that combines opioid-like efficacy without the well known adverse event profile associated with these drugs has been likened to that for the "Holy Grail" of pain therapy.  The rate of occurrence for nausea, vomiting, dizziness, sedation, and constipation, are estimated to occur in "tens of millions" of Americans suffering from acute and chronic pain every year(2).  Incremental costs to the health care system for GI events caused by opioids alone are estimated to range from $4,880 to $36,152 per patient(3).

Therefore, the ability of MoxDuo IR to markedly reduce the occurrence of moderate-severe AEs has important clinical and economic benefits.  Having demonstrated reductions of 50%-75% of adverse events, MoxDuo IR opens the therapeutic window for acute pain patients suffering from moderate to severe pain and provides the potential for significant healthcare cost reductions in the treatment of patients receiving opioid therapy.

About QRxPharma

QRxPharma (ASX: QRX and OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy which focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes.  The Company intends to directly commercialise its products in the US and seek strategic partnerships for worldwide markets.  QRxPharma's lead product candidate, MoxDuo®IR, is in Phase 3 clinical development and has successfully compl
'/>"/>

SOURCE QRxPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... -- STAAR Surgical Company (NASDAQ: STAA ), a leading developer, ... the eye today reported financial results for the second quarter ... , Net Sales of $18.7 Million Down 7% from ... $2.1 Million from the Weakening Euro and Yen , ... , APAC Sales Down 1% Including Korea - Up ...
(Date:7/29/2015)... 29, 2015  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the second quarter ended June 30, 2015. ... HETLIOZ and Fanapt" said Mihael H. Polymeropoulos M.D., Vanda,s ... life cycle management of our products set the stage ... Financial Highlights , Total net product ...
(Date:7/29/2015)... NEWARK, Calif. , July 29, 2015 /PRNewswire/ ... "Company") today announced that its Board of Directors, ... its independent financial and legal advisors, has unanimously ... non-binding proposal from Horizon Pharma plc (NASDAQ: ... outstanding shares of Depomed in an all-stock transaction ...
Breaking Medicine Technology:STAAR Surgical Reports Second Quarter 2015 Results 2STAAR Surgical Reports Second Quarter 2015 Results 3STAAR Surgical Reports Second Quarter 2015 Results 4STAAR Surgical Reports Second Quarter 2015 Results 5STAAR Surgical Reports Second Quarter 2015 Results 6STAAR Surgical Reports Second Quarter 2015 Results 7STAAR Surgical Reports Second Quarter 2015 Results 8STAAR Surgical Reports Second Quarter 2015 Results 9STAAR Surgical Reports Second Quarter 2015 Results 10STAAR Surgical Reports Second Quarter 2015 Results 11STAAR Surgical Reports Second Quarter 2015 Results 12STAAR Surgical Reports Second Quarter 2015 Results 13STAAR Surgical Reports Second Quarter 2015 Results 14STAAR Surgical Reports Second Quarter 2015 Results 15STAAR Surgical Reports Second Quarter 2015 Results 16STAAR Surgical Reports Second Quarter 2015 Results 17STAAR Surgical Reports Second Quarter 2015 Results 18STAAR Surgical Reports Second Quarter 2015 Results 19STAAR Surgical Reports Second Quarter 2015 Results 20STAAR Surgical Reports Second Quarter 2015 Results 21STAAR Surgical Reports Second Quarter 2015 Results 22STAAR Surgical Reports Second Quarter 2015 Results 23STAAR Surgical Reports Second Quarter 2015 Results 24Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 2Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 3Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 4Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 5Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 6Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 7Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 8Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 9Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 10Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 11Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 12Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 13
... PARK, Calif., March 22, 2011 Telome Health, Inc. ... property portfolio. THI will provide telomere length data from ... health monitoring. THI leverages the predictive ... protective caps at the ends of chromosomes, to assess ...
... MOUNT PROSPECT, Ill., March 22, 2011 The National Association ... the prescription monitoring programs (PMPs) of North Dakota , ... agreements to participate in the PMP Interconnect ™ system, ... United States to be linked, providing a more effective means ...
Cached Medicine Technology:Telome Health, Inc. Launches With Exclusive IP Portfolio 2Telome Health, Inc. Launches With Exclusive IP Portfolio 3Three States Sign on to Participate in NABP's Interconnected Prescription Monitoring System 2Three States Sign on to Participate in NABP's Interconnected Prescription Monitoring System 3
(Date:7/29/2015)... ... July 29, 2015 , ... Angelo’s FabriClean, an area ... service: water damage restoration of carpets and rugs. The company will now reverse the ... commercial clients. , An overflowing overhead tank, rain leaking through an accidently left ...
(Date:7/29/2015)... ... July 29, 2015 , ... More than ... service providers of children living with autism will converge upon Penn State to ... , The National Autism Conference will be held Aug. 3-6 at the ...
(Date:7/29/2015)... NY (PRWEB) , ... July 29, 2015 , ... ... Fitness as a sponsor, with its Topricin® Pain Relief and Healing Cream designated ... a firefighter-founded web-based organization that is actively addressing Line of Duty Deaths (LODD) ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... This year, ... record-setting precipitation levels this spring. And, where there is water, mold is not far ... property, offers tips for protecting against water and mold damage. Paul Davis is regularly ...
(Date:7/29/2015)... ... July 29, 2015 , ... CrossFit 269, offering a nationally ... Kalamazoo Strength & Conditioning. , The name change coincides with the release of ... training center over the past three years,” according to Jack Kelly, the center’s ...
Breaking Medicine News(10 mins):Health News:Angelo’s FabriClean Now Offers Water Damage Restoration For Residential and Commercial Accounts 2Health News:Penn State Conference to Address Instruction, Success for Children with Autism 2Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 2Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 3Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 4Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 5Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 6Health News:Paul Davis Offers Tips to Minimize Property Damage and Health Risks This Flood Season 2Health News:Paul Davis Offers Tips to Minimize Property Damage and Health Risks This Flood Season 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4
... received a $1.6 million grant from the National Cancer ... by the body,s immune system, allowing cancer to develop ... Health grant will enable researchers led by Alex Y. ... biomedical engineering at the School of Medicine, and a ...
... , THURSDAY, March 31 (HealthDay News) -- There may ... a common congenital heart defect, a new study suggests. U.S. ... diagnosed with migraines and treated at the Primary Children,s Medical Center ... team checked each child,s heart for a patent foramen ovale (PFO) ...
... immune tolerance field continues to grow. Following the ... October 2009, the Second International Conference on Immune ... their latest research and insights into the mechanisms ... transplantation, autoimmune diseases, inflammation and cancer. This Conference ...
... WEST LAFAYETTE, Ind. - Eating fewer, regular-sized meals with higher ... than eating smaller, more frequent meals, according to new research ... amounts of protein, men who were trying to lose weight ... in late-night desire to eat and had fewer thoughts of ...
... is growing evidence that the risk factors for ... risk factors for developing addiction in adolescence are ... is associated with the highest addiction risk. Traits ... behavioral disinhibition, and devaluation of the future negative ...
... 31 (HealthDay News) -- An antibacterial agent that,s an ingredient ... in the bodies of fish, finds a new study. ... concerns due to its potential hormone-disrupting effects. Bioaccumulation occurs ... unable to metabolize and excrete the chemical quickly enough, allowing ...
Cached Medicine News:Health News:Case Western Reserve receives $1.6M to study tumor cells and immune cell detection 2Health News:2nd International Conference on Immune Tolerance 2Health News:STUDY: 3 square meals a day paired with lean protein help people feel full during weight loss 2Health News:STUDY: 3 square meals a day paired with lean protein help people feel full during weight loss 3Health News:STUDY: 3 square meals a day paired with lean protein help people feel full during weight loss 4Health News:Different genes influence smoking risk during adolescence and adulthood 2Health News:Antibacterial Soap Additive Accumulates in Fish: Study 2
Anti-Tg and Anti-TPO are two major autoantibodies implicated in autoimmune related thyroiditis and aid in the differential diagnosis of Hashimoto's thyroiditis and Graves' disease....
... is an automated, turbidimetric, whole- blood assay ... the ability of activated platelets to bind ... of the VerifyNow IIb/IIIa assay device contains ... this analysis. Within the well is an ...
... The Company's first commercial product is ... with single-use, disposable assay devices . The ... products are direct use of a vacuum-type ... a result in minutes. VerifyNow IIb/IIIa, the ...
... ComboMap system provides both pressure and ... singly or in a combined screen ... SmartWire and Volcano's unique Doppler FloWire. ... valuable tools to assess ambiguous or ...
Medicine Products: